U.S. based Merck & Co. (NYSE:MRK) was 8th in total sales and #7 ($3.62 bn EUR)in R&D spending in 2006. Merck has had success with the U.K mandating HPV for all school age girls and its vaccine, Gardasil, is in the running as the vaccine of choice. Tasinga, an orally available inhibitor of Bcr-Abl, c-Kit, PDGF-R and related receptor tyrosine kinases for the potential treatment of various types of leukemia made Thomson Scientific's list of Most Promising Drugs. Merck also received FDA approval of its HIV drug Isentress.
Pending Approval:
MK-0518 (raltegravir) - HIV
MK-0517 - chemotherapy-induced nausea and vomiting (approvable)
Phase III
MK-0524A - Atherosclerosis
MK-0524B - Atherosclerosis
MK-0364 (taranabant) - Obesity
MK-0974 - Migraine
MK-8669 - Cancer
[Source: FierceBiotech]
» 2007 Edition of the European Commission's Report of R&D Spending from PharmaGazette
The 2007 edition of the European Commission's annual report of research and development spending places Pfizer Inc. at the top of the heap outspending all other industries.Pharmaceuticals and biotechnology became the top R&D spenders beating ou... [Read More]
Tracked on: December 12, 2007 10:53 AM | Permalink to Trackback